Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma

Neoplasma

Volumn 55, Issue 3, 2008, Pages 266-272

  Lu, Shan Ming ^a   Xiao, Ping ^a   Xue, Ling ^a   Che, Li Hong ^a   Yang, Ping ^a   Li, Yang ^a   Qiao, Hui ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

MICA; NKG2D; Osteosarcoma; sMICA

Indexed keywords

HLA A ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; HLA ANTIGEN CLASS 1; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; BONE TISSUE; CANCER RECURRENCE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; UPREGULATION; WESTERN BLOTTING; BONE TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

ADOLESCENT; ADULT; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; RNA, MESSENGER;

EID: 49049100533     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. LONGHI A, ERRANI C, De PAOLIS M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32: 423-436
2. WITLOX MA, LAMFERS ML, WUISMAN PI, et al. Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone 2007; 40: 797-812.
3. MERCHANT MS, MELCHIONDA F, SINHA M, et al. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother 2007; 56: 1037-1046
4. TRIEB K, LECHLEITNER T, LANG S, et al. Evaluation of HLA-DR expression and T-lymphocyte infiltration inosteosarcoma. Pathol Res Pract 1998; 194: 679-684 (Pubitemid 28523941)
5. RAULET DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-790
6. COUDERT JD, HELD W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006; 16: 333-343
7. GROH V, WU J, YEE C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738
8. OSAKI T, SAITO H, YOSHIKAWA T, et al. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 2007; 13: 382-387
9. WIEMANN K, MITTRUCKER HW, FEGER U, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175: 720-729 (Pubitemid 41094952)
10. FRIESE MA, PLATTEN M, LUTZ SZ, et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63: 8996-9006. (Pubitemid 38064081)
11. RAFFAGHELLO L, PRIGIONE I, AIROLDI I, CAMORIANO M, LEVRERI I, GAMBINI C, PENDE D, STEINLE A, FERRONE S, PISTOIA V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-568
12. MOLINERO LL, FUERTES MB, GIRART MV, FAINBOIM L, RABINOVICH GA, COSTAS MA, ZWIRNER NW. NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol 2004; 173: 5583-5590
13. DOUBROVINA ES, DOUBROVIN MM, VIDER E, et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171: 6891-6899
14. WU JD, HIGGINS LM, STEINLE A, et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-568
15. JINUSHI M, TAKEHARA T, TATSUMI T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354-361
16. BUSCHE A, GOLDMANN T, NAUMANN U, et al. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther 2006; 17: 135-146
17. XU X, RAO G, GAFFUD MJ, et al. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J Clin Endocrinol Metab 2006; 91: 2704-2712
18. BOISSEL N, REA D, TIENG V, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176: 5108-5116
19. ROUTES JM, RYAN S, MORRIS K, et al. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 2005; 202: 1477-1482
20. BUI JD, CARAYANNOPOULOS LN, LANIER LL, et al. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 2006; 176: 905-913
21. GASSER S, ORSULIC S, BROWN EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190
22. KRIEGESKORTE AK, GEBHARDT FE, PORCELLINI S, et al. NKG2D-independent suppression of T cell proliferation by H60 and MICA. Proc Natl Acad Sci U S A 2005; 102: 11805-11810